Drug Profile
HC 017 AA
Alternative Names: HC017AALatest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator HCell
- Class Anti-inflammatories; Skin disorder therapies
- Mechanism of Action Angiogenesis inducing agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alopecia areata
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Alopecia areata(In adolescents, In children) in South Korea (Topical, Injection)
- 15 Jan 2018 Preclinical trials in Alopecia areata (In children, In adolescents) in South Korea (Topical)
- 15 Jan 2018 HC 017 AA receives Orphan Drug status for Alopecia areata (In children, In adolescents) in USA